Cable Hill Partners, LLC Gilead Sciences, Inc. Transaction History

Cable Hill Partners, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 04, 2023	BUY	$77.31 - $88.08 $2,551 - $2,906	33 Added 1.2%	2,785 $231,000
Q4 2022 Feb 06, 2023	BUY	$62.32 - $89.47 $171,504 - $246,221	2,752 New	2,752 $236,000
Q2 2019 Aug 06, 2019	SELL	$61.87 - $69.38 $24,438 - $27,405	-395 Closed	0 $0
Q1 2019 May 10, 2019	BUY	$62.53 - $70.05 $2,000 - $2,241	32 Added 8.82%	395 $26,000
Q2 2018 Aug 03, 2018	SELL	$64.88 - $75.68 $21,929 - $25,579	-338 Reduced 48.22%	363 $25,000
Q4 2017 Feb 22, 2018	SELL	$71.15 - $83.52 $9,889 - $11,609	-139 Reduced 16.55%	701 $52,000
Q3 2017 Oct 27, 2017	SELL	$72.11 - $85.47 $19,974 - $23,675	-277 Reduced 24.8%	840 $68,000
Q2 2017 Aug 14, 2017	BUY	N/A	1,117	1,117 $79,000

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Cable Hill Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Cable Hill Partners, LLC with notifications on news.